Trial · NCT03304054
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - MuSK | Baseline (Day 0) MG-ADL Total Raw Score | 4.96 | Standard Deviation 2.915 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - MuSK | Baseline (Day 0) MG-ADL Total Raw Score | 3.86 | Standard Deviation 2.103 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - AChR | Baseline (Day 0) MG-ADL Total Raw Score | 6.14 | Standard Deviation 3.388 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - AChR | Baseline (Day 0) MG-ADL Total Raw Score | 7.00 | Standard Deviation 4.175 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - MuSK | Post-Baseline(Day 10 or time at which a patient discontinued treatment) MG-ADL Total Raw Score | 6.00 | Standard Deviation 3.658 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - MuSK | Post-Baseline(Day 10 or time at which a patient discontinued treatment) MG-ADL Total Raw Score | 6.11 | Standard Deviation 3.19 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - AChR | Post-Baseline(Day 10 or time at which a patient discontinued treatment) MG-ADL Total Raw Score | 4.71 | Standard Deviation 3.147 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - AChR | Post-Baseline(Day 10 or time at which a patient discontinued treatment) MG-ADL Total Raw Score | 10.38 | Standard Deviation 3.583 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - MuSK | CFB MG-ADL Total Score | 1.04 | Standard Deviation 2.980 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - MuSK | CFB MG-ADL Total Score | 2.25 | Standard Deviation 3.658 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - AChR | CFB MG-ADL Total Score | -1.43 | Standard Deviation 2.225 | Score on a Scale |
| Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - AChR | CFB MG-ADL Total Score | 3.38 | Standard Deviation 2.825 | Score on a Scale |
| Quantitative Myasthenia Gravis (QMG) Total Score Summary Statistics by Time Point and MG Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - MuSK | Baseline (Day 0) QMG Total Raw Score | 10.00 | Standard Deviation 3.873 | Score on a Scale |
| Quantitative Myasthenia Gravis (QMG) Total Score Summary Statistics by Time Point and MG Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - MuSK | Baseline (Day 0) QMG Total Raw Score | 8.64 | Standard Deviation 3.744 | Score on a Scale |
| Quantitative Myasthenia Gravis (QMG) Total Score Summary Statistics by Time Point and MG Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - AChR | Baseline (Day 0) QMG Total Raw Score | 10.57 | Standard Deviation 3.359 | Score on a Scale |
| Quantitative Myasthenia Gravis (QMG) Total Score Summary Statistics by Time Point and MG Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - AChR | Baseline (Day 0) QMG Total Raw Score | 14.13 | Standard Deviation 4.155 | Score on a Scale |
| Quantitative Myasthenia Gravis (QMG) Total Score Summary Statistics by Time Point and MG Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - MuSK | Post-Baseline (day 10 or time at which a patient discontinued treatment early) QMG Total Raw Score | 11.19 | Standard Deviation 5.367 | Score on a Scale |
| Quantitative Myasthenia Gravis (QMG) Total Score Summary Statistics by Time Point and MG Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - MuSK | Post-Baseline (day 10 or time at which a patient discontinued treatment early) QMG Total Raw Score | 10.16 | Standard Deviation 3.648 | Score on a Scale |
| Quantitative Myasthenia Gravis (QMG) Total Score Summary Statistics by Time Point and MG Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Amifampridine Phosphate - AChR | Post-Baseline (day 10 or time at which a patient discontinued treatment early) QMG Total Raw Score | 10.86 | Standard Deviation 3.024 | Score on a Scale |
| Quantitative Myasthenia Gravis (QMG) Total Score Summary Statistics by Time Point and MG Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Placebo - AChR | Post-Baseline (day 10 or time at which a patient discontinued treatment early) QMG Total Raw Score | 14.43 | Standard Deviation 3.952 | Score on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03304054/results